The Effects of Framework Mutations at the Variable Domain Interface on Antibody Affinity Maturation in an HIV-1 Broadly Neutralizing Antibody Lineage.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 11 02 2020
accepted: 10 06 2020
entrez: 9 8 2020
pubmed: 9 8 2020
medline: 15 4 2021
Statut: epublish

Résumé

Understanding affinity maturation of antibodies that can target many variants of HIV-1 is important for vaccine development. While the antigen-binding site of antibodies is known to mutate throughout the co-evolution of antibodies and viruses in infected individuals, the roles of the mutations in the antibody framework region are not well understood. Throughout affinity maturation, the CH103 broadly neutralizing antibody lineage, from an individual designated CH505, altered the orientation of one of its antibody variable domains. The change in orientation was a response to insertions in the variable loop 5 (V5) of the HIV envelope. In this study, we generated CH103 lineage antibody variants in which residues in the variable domain interface were mutated, and measured the binding to both autologous and heterologous HIV-1 envelopes. Our data show that very few mutations in an early intermediate antibody of the lineage can improve binding toward both autologous and heterologous HIV-1 envelopes. We also crystallized an antibody mutant to show that framework mutations alone can result in a shift in relative orientations of the variable domains. Taken together, our results demonstrate the functional importance of residues located outside the antigen-binding site in affinity maturation.

Identifiants

pubmed: 32765530
doi: 10.3389/fimmu.2020.01529
pmc: PMC7379371
doi:

Substances chimiques

Antibodies, Neutralizing 0
Epitopes 0
HIV Antibodies 0
HIV Envelope Protein gp120 0
Immunoglobulin Variable Region 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1529

Subventions

Organisme : NIGMS NIH HHS
ID : P30 GM124165
Pays : United States
Organisme : NIH HHS
ID : S10 OD021527
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2020 Zhou, Zaidi, Ton and Fera.

Références

Immunity. 2015 Dec 15;43(6):1053-63
pubmed: 26682982
MAbs. 2014;6(5):1274-82
pubmed: 25517312
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):264-9
pubmed: 23175789
Structure. 2016 Aug 2;24(8):1346-1357
pubmed: 27477385
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9
pubmed: 12644702
J Exp Med. 2010 Aug 30;207(9):1995-2002
pubmed: 20679402
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W375-83
pubmed: 17452350
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
Sci Rep. 2017 Mar 28;7:45259
pubmed: 28349921
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):E486-E495
pubmed: 28057863
Elife. 2018 Feb 14;7:
pubmed: 29442996
Science. 2010 Aug 13;329(5993):811-7
pubmed: 20616231
Nature. 2014 May 1;509(7498):55-62
pubmed: 24590074
Biochemistry. 1998 Sep 22;37(38):13120-7
pubmed: 9748318
Nature. 2013 Apr 25;496(7446):469-76
pubmed: 23552890
J Virol. 2011 Sep;85(17):8954-67
pubmed: 21715490
Science. 1997 Jun 13;276(5319):1665-9
pubmed: 9180069
Nat Struct Mol Biol. 2018 Feb;25(2):115-121
pubmed: 29396418
Cell. 2013 Mar 28;153(1):126-38
pubmed: 23540694
Front Immunol. 2018 Feb 01;9:117
pubmed: 29449843
Nat Commun. 2018 Mar 16;9(1):1111
pubmed: 29549260
Cell. 2014 Sep 25;159(1):69-79
pubmed: 25259921
PLoS Pathog. 2016 Aug 25;12(8):e1005815
pubmed: 27560183
Science. 2019 Dec 6;366(6470):
pubmed: 31806786
Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22373-80
pubmed: 21173256
Sci Transl Med. 2017 Mar 15;9(381):
pubmed: 28298420
Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10275-80
pubmed: 24982157
Methods Enzymol. 1994;240:615-45
pubmed: 7823851
PLoS One. 2018 Apr 9;13(4):e0195442
pubmed: 29630643
Science. 2011 Sep 16;333(6049):1633-7
pubmed: 21764753
Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10370-4
pubmed: 7937957
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21
pubmed: 20124702
Cell Host Microbe. 2018 Jun 13;23(6):759-765.e6
pubmed: 29861171
Nature. 2003 Mar 20;422(6929):307-12
pubmed: 12646921
Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):32-41
pubmed: 17164524
Nat Commun. 2019 Feb 8;10(1):654
pubmed: 30737386
Nat Protoc. 2006;1(6):2876-90
pubmed: 17406547
J Virol. 2008 Dec;82(23):11651-68
pubmed: 18815292
PLoS Pathog. 2013;9(11):e1003754
pubmed: 24278016

Auteurs

Jeffrey O Zhou (JO)

Department of Chemistry and Biochemistry, Swarthmore College, Swarthmore, PA, United States.

Hussain A Zaidi (HA)

Department of Chemistry and Biochemistry, Swarthmore College, Swarthmore, PA, United States.

Therese Ton (T)

Department of Biology, Swarthmore College, Swarthmore, PA, United States.

Daniela Fera (D)

Department of Chemistry and Biochemistry, Swarthmore College, Swarthmore, PA, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH